Climb Bio, Inc. (CLYM)

Take Impact Assessment

Impact Scorecard
About

Overall impact

C (59)

Commentary

Climb Bio, Inc. is an average overall performer. With a 'C' rating of 59.3 for overall impact (61st percentile compared to all companies), Climb Bio, Inc. ranks 526th out of 677 industry peers, behind Allena Pharmaceuticals, Pluristem Therapeutics, Cell Source and 521 others, and ahead of Aldeyra Therapeutics, Aptose Biosciences, Apellis Pharmaceuticals and 148 others. On top material causes for Climb Bio, Inc. 's industry (Biotechnology), Climb Bio, Inc. performs well in Child and Maternal Health (95.4 score), Child and Maternal Health (95.4), Disease Eradication (96.2) and 11 other causes where it received an 'A' score and performs poorly in Sustainable Use of Natural Resources (27.0 score), Reduced Waste (10.5), Reduced Waste (10.5) and 8 other causes where it received a 'D' or 'F' score.

... read full commentary

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Anti-abortion support
Anti-Israel
Anti-personnel mines
Anti-social publishing
Arctic drilling
Banned pesticides and chemicals
Banned pharmaceuticals
Biological and chemical weapons
Cannabis
Child safety
Cluster munitions
Coal
Conflict minerals
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Illegal activities
ILO Conventions
Interest-based products
Iran
Land use and biodiversity
Military contracting
Misleading communication
Music
Myanmar
Non-sustainable palm oil
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact

Cause			CLYM

Peer rank

Overall impact

Log in to view this information

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Anti-abortion support
Anti-Israel
Anti-personnel mines
Anti-social publishing
Arctic drilling
Banned pesticides and chemicals
Banned pharmaceuticals
Biological and chemical weapons
Cannabis
Child safety
Cluster munitions
Coal
Conflict minerals
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Illegal activities
ILO Conventions
Interest-based products
Iran
Land use and biodiversity
Military contracting
Misleading communication
Music
Myanmar
Non-sustainable palm oil
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Employees

Sector

Health Care

Industry

Biotechnology

Sub-industry

Biotechnology

SASB industry

Biotechnology & Pharmaceuticals

Headquarters

#<Country/State:0x0000ffff78c29610>, United States

Share classes

CLYM

More info

https://climbbio.com

Description

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Material causes

Ethos considers the following causes material for Climb Bio, Inc. , based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

Access to affordable healthcare

Ensure universal access to affordable, quality healthcare

Accountable institutions

Build accountable and inclusive institutions at all levels

Child and maternal health

End preventable deaths of mothers and children, support reproductive health everywhere

Decent, safe work opportunities

Promote full and productive employment for all, in safe work environments

Disaster readiness and effective aid

Be prepared for natural disasters and provide effective aid when disasters happen

Disease eradication

Eradicate infectious and non-communicable diseases